• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.

作者信息

de Stefano G, Iodice V, Farella N

机构信息

Ultrasound Unit for Infectious Diseases, AORN dei Colli, Naples, Italy.

出版信息

J Gastrointest Cancer. 2015 Dec;46(4):430-3. doi: 10.1007/s12029-015-9720-5.

DOI:10.1007/s12029-015-9720-5
PMID:25894635
Abstract
摘要

相似文献

1
Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.一名老年肝癌患者对全剂量索拉非尼治疗的完全缓解：病例报告
J Gastrointest Cancer. 2015 Dec;46(4):430-3. doi: 10.1007/s12029-015-9720-5.
2
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.索拉非尼治疗晚期肝细胞癌后的完全放射学缓解
Tunis Med. 2015 Jun;93(6):350-2.
3
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.索拉非尼：晚期肝细胞癌及其他病症的金标准疗法。
Future Oncol. 2015;11(16):2263-6. doi: 10.2217/fon.15.161.
4
Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.索拉非尼治疗晚期肝细胞癌实现持续完全缓解
J Dig Dis. 2015 Sep;16(9):537-40. doi: 10.1111/1751-2980.12270.
5
Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.单药索拉非尼治疗转移性肝细胞癌的持续完全缓解
J Gastrointest Cancer. 2013 Mar;44(1):98-101. doi: 10.1007/s12029-012-9438-6.
6
Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.多结节性肝癌患者索拉非尼剂量减少后的部分缓解及心血管功能恢复
J Gastrointest Cancer. 2012 Sep;43 Suppl 1:S89-92. doi: 10.1007/s12029-011-9328-3.
7
Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.中性粒细胞与淋巴细胞比值在接受索拉非尼治疗的晚期肝细胞癌患者中的预测作用
Asian Pac J Cancer Prev. 2014;15(2):1063. doi: 10.7314/apjcp.2014.15.2.1063.
8
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.经索拉非尼治疗后实现完全缓解的晚期肝细胞癌患者的长期预后。
Clin Mol Hepatol. 2015 Sep;21(3):287-94. doi: 10.3350/cmh.2015.21.3.287. Epub 2015 Sep 30.
9
Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.索拉非尼治疗后肝移植复发性晚期肝细胞癌完全缓解：一例报告
Transplant Proc. 2016 Jan-Feb;48(1):247-50. doi: 10.1016/j.transproceed.2015.11.012.
10
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.索拉非尼治疗后经射频消融实现晚期肝细胞癌完全缓解
World J Gastroenterol. 2015 Feb 28;21(8):2568-72. doi: 10.3748/wjg.v21.i8.2568.

本文引用的文献

1
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.早期皮肤不良事件预示着索拉非尼治疗 HCC 患者的更好结局。
J Hepatol. 2014 Aug;61(2):318-24. doi: 10.1016/j.jhep.2014.03.030. Epub 2014 Apr 2.
2
Hepatocellular carcinoma: sorafenib: for once age is not an issue.肝细胞癌：索拉非尼：年龄不再是问题。
Nat Rev Gastroenterol Hepatol. 2014 May;11(5):273-4. doi: 10.1038/nrgastro.2014.48. Epub 2014 Apr 1.
3
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
索拉非尼治疗的已确诊肝硬化和肝细胞癌患者的生存预测因素。
World J Gastroenterol. 2014 Jan 21;20(3):786-94. doi: 10.3748/wjg.v20.i3.786.
4
Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma.索拉非尼在80岁及以上老年晚期肝细胞癌患者中的疗效和安全性。
Hepatol Res. 2014 Dec;44(13):1329-38. doi: 10.1111/hepr.12308. Epub 2014 Apr 2.
5
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?索拉非尼治疗肝细胞癌患者的疗效是否受年龄影响？
Expert Rev Anticancer Ther. 2013 Dec;13(12):1355-61. doi: 10.1586/14737140.2013.859989. Epub 2013 Nov 13.
6
Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.索拉非尼在老年晚期肝细胞癌中的靶向治疗：关注焦点。
Drugs Aging. 2013 Nov;30(11):887-92. doi: 10.1007/s40266-013-0124-6.
7
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.舒尼替尼与索拉非尼治疗晚期肝细胞癌的随机对照 III 期临床试验结果。
J Clin Oncol. 2013 Nov 10;31(32):4067-75. doi: 10.1200/JCO.2012.45.8372. Epub 2013 Sep 30.
8
Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series.索拉非尼治疗老年晚期肝细胞癌患者：病例系列研究。
Oncology. 2013;84(5):265-72. doi: 10.1159/000345558. Epub 2013 Feb 20.
9
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.年龄对索拉非尼靶向治疗肝硬化合并肝细胞癌患者的毒性和疗效的影响。
Med Oncol. 2013 Mar;30(1):446. doi: 10.1007/s12032-012-0446-y. Epub 2013 Jan 10.
10
Geriatric oncology research to improve clinical care.老年肿瘤学研究以改善临床护理。
Nat Rev Clin Oncol. 2012 Oct;9(10):571-8. doi: 10.1038/nrclinonc.2012.125. Epub 2012 Jul 24.